LDE225 and Paclitaxel in Solid Tumors

NCT01954355 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
Ovarian Cancer

Interventions

DRUG: LDE225
DRUG: Paclitaxel

Sponsor

Swiss Cancer Institute